FDA opens FY2026 veterinary drug research grant applications: full analysis

FDA is reopening a key federal funding lane for veterinary drug research. On May 4, 2026, the FDA’s Center for Veterinary Medicine announced that it is accepting fiscal year 2026 applications for Animal and Veterinary Innovation Centers, or AVICs, with a focus on aquaculture, minor ruminant drugs, human food safety for minor species drugs, and antimicrobial use and stewardship. CVM said it may initiate up to five grants, and that award funding can be renewed for up to four years, depending on progress and available funds. (fda.gov)

The announcement builds on FDA’s Animal and Veterinary Innovation Agenda, released in September 2023, which laid out a broader plan to spur innovation in animal health, animal biotechnology, and animal food regulation. AVICs were established in 2024 as one of the agenda’s practical mechanisms for moving that strategy into funded research partnerships. FDA’s framing has been consistent: use academic collaborations to fill regulatory science gaps, support development of needed products, and address animal, human, and environmental health together through a One Health lens. (fda.gov)

This year’s priority list is narrower and more targeted than the first AVIC round. According to FDA, applicants should propose work that addresses regulatory science gaps in aquaculture drug development, develops viable drugs for minor ruminant species including sheep and goats, uses innovative approaches to meet human food safety requirements for minor species drugs, or generates antimicrobial-use research that improves understanding of judicious use of medically important antimicrobials in veterinary medicine. Applications must be submitted through NIH ASSIST or Grants.gov by June 12, 2026, and FDA has scheduled a virtual technical session for May 11, 2026, from 1:00 to 2:30 p.m. EDT. (fda.gov)

The structure also reflects lessons from the program’s first year. In September 2024, FDA announced four inaugural AVIC partnerships: University of Wisconsin-Madison for genome-edited chickens and avian virus resistance, UC Davis for gene editing in livestock, Kansas State University for analgesic efficacy models in food animals, and the University of Arkansas for blackhead disease research in turkeys. Those awards showed that FDA was willing to use the AVIC model for both emerging technologies and stubborn unmet needs in food and production animals. (fda.gov)

The underlying notice of funding opportunity gives more context for how FDA sees these centers. The agency has described AVICs as cooperative agreements with academic institutions meant to support products for minor uses in major species, minor species, and other unmet veterinary medical needs that affect animal health, public health, production, or the environment. In the original 2024 funding notice, FDA said future-year award numbers and amounts would depend on appropriations, underscoring that this is both a scientific and budget-dependent initiative. (grants.nih.gov)

Expert reaction was limited in public sources immediately available after the May 4 announcement, but FDA’s own messaging around the Animal and Veterinary Innovation Agenda has emphasized that the agency is trying to create stronger product pipelines and clearer regulatory pathways for areas where commercial incentives are often weak. That matters in categories like minor species and aquaculture, where developers have historically faced small markets, thin data, and complex approval requirements. FDA has made similar arguments in its separate minor use and minor species grant programs, which are explicitly designed to help overcome financial roadblocks for limited-market animal drugs. (fda.gov)

Why it matters: For veterinary professionals, this is less about a single grant notice and more about where federal veterinary regulation is putting its weight. The chosen topics map directly to areas where practitioners and producers often have too few approved tools, especially in food animal and minor species practice. If these centers generate usable data for safety, efficacy, antimicrobial stewardship, or food residue questions, they could help de-risk future submissions and expand the pipeline for products that otherwise struggle to reach market. That could eventually affect prescribing options, compliance expectations, and conversations with producers and pet parents about evidence-based use of therapies in underserved species and indications. (fda.gov)

What to watch: The next milestones are the May 11 technical session, the June 12, 2026 application deadline, and then the makeup of any awardees. The bigger question is whether FDA continues to scale AVICs as a standing part of its innovation agenda, especially as the agency also signals broader plans to sharpen CVM’s scientific and regulatory development functions through future programs such as ADVANce. (fda.gov)